Department of Biotechnology Chemistry and Pharmacy, University of Siena, Siena, Italy.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Cancer Res. 2020 Aug 15;80(16):3319-3330. doi: 10.1158/0008-5472.CAN-19-2416. Epub 2020 Jun 19.
The presence of immunosuppressive macrophages that become activated in the tumor microenvironment constitutes a major factor responsible for tumor growth and malignancy. In line with this knowledge, we report here that macrophage proliferation is a significant feature of advanced stages of cancer. Moreover, we have found that a high proportion of proliferating macrophages in human tumors express ERK5. ERK5 was required for supporting the proliferation of macrophages in tumor grafts in mice. Furthermore, myeloid ERK5 deficiency negatively impacted the proliferation of both resident and infiltrated macrophages in metastatic lung nodules. ERK5 maintained the capacity of macrophages to proliferate by suppressing p21 expression to halt their differentiation program. Collectively, these data provide insight into the mechanism underpinning macrophage proliferation to support malignant tumor development, thereby strengthening the value of ERK5-targeted therapies to restore antitumor immunity through the blockade of protumorigenic macrophage activation. SIGNIFICANCE: These findings offer a new rationale for anti-ERK5 therapy to improve cancer patient outcomes by blocking the proliferative activity of tumor macrophages.
肿瘤微环境中被激活的免疫抑制性巨噬细胞的存在是导致肿瘤生长和恶性的主要因素。根据这一知识,我们在这里报告称,巨噬细胞增殖是癌症晚期的一个重要特征。此外,我们发现人类肿瘤中增殖的巨噬细胞中有很大比例表达 ERK5。ERK5 对于支持在小鼠肿瘤移植物中巨噬细胞的增殖是必需的。此外,髓系 ERK5 缺陷会对转移性肺结节中常驻和浸润的巨噬细胞的增殖产生负面影响。ERK5 通过抑制 p21 表达来阻止其分化程序,从而维持巨噬细胞的增殖能力。总的来说,这些数据提供了对支持恶性肿瘤发展的巨噬细胞增殖机制的深入了解,从而增强了针对 ERK5 的治疗方法的价值,通过阻断促肿瘤巨噬细胞的激活来恢复抗肿瘤免疫。
这些发现为抗-ERK5 治疗提供了新的依据,通过阻断肿瘤巨噬细胞的增殖活性来改善癌症患者的预后。